Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The results of Mehra et al in The Lancet have had a considerable impact on public health practice and research, halted trials and caused considerable concern to participants and patients enrolled in randomised controlled trials (RCTs). This has led many researchers around the world to scrutinise in detail the publication and outline their concerns in this letter to Richard Horton, editor of The Lancet.

Similar stories

Immediate policy changes urgently needed as drug-resistant malaria spreads in East Africa

The efficacy of artemisinin derivatives, the cornerstone of current treatments for malaria, is being compromised in Africa where over 1,000 children are estimated to die each day from the disease. The spread of artemisinin-resistant malaria parasites across East Africa and beyond could result in millions more deaths without immediate health policy changes, warn experts in a paper published in Science.